Ftse Mib
34.625,80
0,83%
DAX
18.772,85
0,50%
S&P 500
5.221,29
0,14%
NASDAQ
16.335,40
-0,07%
Bitcoin
60.822,75
-3,53%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aadi Bioscience Inc (AADI) Aadi Bioscience Inc (AADI) Notizie

AADI

Aadi Bioscience (AADI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AADI
DataOraFonteTitoloSimboloCompagnia
08/05/202422:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AADIAadi Bioscience Inc
08/05/202414:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AADIAadi Bioscience Inc
08/05/202414:00PR Newswire (US)Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate UpdateNASDAQ:AADIAadi Bioscience Inc
01/05/202414:01PR Newswire (US)Aadi Bioscience to Report First Quarter 2024 Results and Corporate UpdateNASDAQ:AADIAadi Bioscience Inc
09/04/202414:00PR Newswire (US)Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual MeetingNASDAQ:AADIAadi Bioscience Inc
17/03/202413:00PR Newswire (US)Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)NASDAQ:AADIAadi Bioscience Inc
13/03/202413:00PR Newswire (US)Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate UpdateNASDAQ:AADIAadi Bioscience Inc
06/03/202414:00PR Newswire (US)Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate UpdateNASDAQ:AADIAadi Bioscience Inc
05/03/202422:30PR Newswire (US)Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:AADIAadi Bioscience Inc
05/03/202401:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
01/03/202422:08PR Newswire (US)Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComaNASDAQ:AADIAadi Bioscience Inc
01/03/202419:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AADIAadi Bioscience Inc
26/02/202422:05PR Newswire (US)Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:AADIAadi Bioscience Inc
12/02/202423:21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AADIAadi Bioscience Inc
12/02/202423:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AADIAadi Bioscience Inc
26/01/202422:05PR Newswire (US)Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers SymposiumNASDAQ:AADIAadi Bioscience Inc
19/01/202422:05PR Newswire (US)Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers SymposiumNASDAQ:AADIAadi Bioscience Inc
14/12/202322:05PR Newswire (US)Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating AlterationsNASDAQ:AADIAadi Bioscience Inc
08/11/202322:28Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AADIAadi Bioscience Inc
08/11/202314:00PR Newswire (US)Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate UpdateNASDAQ:AADIAadi Bioscience Inc
06/11/202322:05PR Newswire (US)Aadi Bioscience to Participate in Jefferies London Healthcare ConferenceNASDAQ:AADIAadi Bioscience Inc
01/11/202321:05PR Newswire (US)Aadi Bioscience to Report Third Quarter 2023 Results and Operational UpdateNASDAQ:AADIAadi Bioscience Inc
19/10/202322:05PR Newswire (US)Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global MeetingNASDAQ:AADIAadi Bioscience Inc
12/10/202322:05PR Newswire (US)Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:AADIAadi Bioscience Inc
05/10/202322:05PR Newswire (US)Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical SymposiumNASDAQ:AADIAadi Bioscience Inc
04/10/202300:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
03/10/202322:05PR Newswire (US)Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)NASDAQ:AADIAadi Bioscience Inc
02/10/202314:00PR Newswire (US)Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive OfficerNASDAQ:AADIAadi Bioscience Inc
05/09/202314:00PR Newswire (US)Aadi Bioscience to Participate at Upcoming Investor ConferencesNASDAQ:AADIAadi Bioscience Inc
09/08/202314:00PR Newswire (US)Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate UpdateNASDAQ:AADIAadi Bioscience Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AADI

La tua Cronologia

LSE
93ES
Perm Mast 42
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network